Lewy Body Dementia (LBD) Test

SYNTap-CSF is the biomarker test to diagnose whether a person has Lewy Body Dementia. It offers doctors an accurate diagnosis of LBD on a molecular level. 

What is SYNTap-CSF

The Synuclein biomarker test detects misfolded Synuclein aggregates in LBD patients at all stages. 

How Does the SYNTap Test Work:

Using a drop of cerebral spinal fluid (CSF), our diagnostic test detects the presence of misfolded Synuclein, the prion-protein damaging the brain in Lewy Body Dementia.

Learn more about the science behind our test.

Who Should Take This Test:

The SYNTap-CSF is a biomarker test for doctors to diagnose Lewy Body Dementia amongst the people who show:

  1. Early symptoms of a memory disorder that could be Alzheimer’s or some other cognitive disease.
  2. Signs of cognitive decline PLUS symptoms of autonomic dysfunction, including sleep disorders, constipation, heart rate problems, or fainting spells.
  3. Signs of cognitive decline PLUS signs of motor problems, including rigidity, tremor, shuffling or leaning to one side.

Physicians use different medicines to treat Lewy Body Dementia and Alzheimer’s at the early stages. Using the wrong medications may worsen both cognitive and motor symptoms. Therefore, it is highly critical to determine whether the patient has LBD versus Alzheimer’s as early as possible. 

The SYNTap biomarker test helps doctors make informed treatment choices that benefit the patient. 

Play Video

All patients with Lewy Body Dementia carry misfolded Synuclein aggregates at all stages. 

Hence, a positive SYNTap-CSF test can effectively differentiate LBD from Alzheimer’s or other dementia.

Watch this video to learn more about the misfolded proteins that drive neurodegenerative diseases.

How Does SYNTap Test Benefit LBD Patients?

The SYNTap-CSF test benefits people showing signs of cognitive decline, shared symptoms between Alzheimer’s and Lewy Body Dementia, in the early stages.

SYNTap-CSF helps doctors diagnose patients with cognitive disorders by detecting LBD and ruling-out Alzheimer’s to treat patients with the right medicines early.

Accurate and early diagnosis means effective treatments, reduced anxiety, frustration, and financial burden. It’s a relief for the patient as well as for all loved ones.

Amprion - hero images - 77
Accurate and early diagnosis means effective treatments, reduced anxiety, frustration and financial burden. It’s a relief for the patient as well as for all loved ones.

What Does A Negative Test Mean?

A negative test result means the absence of detectable Synuclein aggregates in the sample.

In plain speak, this negative SynTap-CSF test effectively rules out LBD.

Patients with a negative SynTap-CSF test should switch to diagnostic protocols for Alzheimer’s, Vascular Dementia, and Frontotemporal Dementia, among others. These protocols usually involve a complex series of imaging, biomarker, and cognitive tests.

Once the SynTap-CSF test has ruled out LBD, doctors, and patients can focus confidently on other possible causes of cognitive decline and memory loss.

Why Use Cerebral Spinal Fluid (CSF) Instead of Blood?

Amprion’s research has demonstrated that CSF represents the most reliable sample to detect protein misfolding in the brain, especially during the early LBD stage.  

When misfolded Synuclein is detectable in the blood, it means the prion-particles have managed to replicate and amass an army of Synuclein prions so large that they’ve breached the blood-brain barrier, traveling throughout the body via the bloodstream. 

A test using cerebral spinal fluid (CSF) reflects misfolded Synuclein and pathology in the brain exclusively. By contrast, a blood test reflects pathology in the entire body, including the brain.

Therefore, CSF testing represents the most accurate and reliable test for neurodegenerative diseases. This is particularly true in the early stages of the disease when misfolded Synuclein is minimal inside the brain.

Amprion - hero images - 47

A test using cerebral spinal fluid (CSF) reflects misfolded Synuclein and pathology in the brain exclusively. By contrast, a blood test reflects pathology in the entire body, including the brain.

Therefore, CSF testing represents the most accurate and reliable test for neurodegenerative diseases. This is particularly true in the early stages of the disease when misfolded Synuclein is minimal inside the brain.

GET THE SYNTap-CSF TEST

This biomarker test detects misfolded Synuclein, a prion-protein driving LBD and other dementias. It’s an effective companion diagnostic to distinguish LBD vs. Alzheimer’s dementias. Sign up for this test now to receive email alerts on testing availabilities.

Blood Test For LBD

In addition to our CSF test, we anticipate rolling out a blood test for misfolded Synuclein within the next 24-months.

Who Benefits From the Blood Test?

The blood test will benefit people who have higher risk factors of LBD, including:

  • Genetic, 
  • Environmental and 
  • Occupational risk factors. 

Through our blood test, your doctor can effectively monitor the development of misfolded Synuclein in the body, though at lower sensitivity than CSF.

If you’re interested in taking the LBD blood test, join our email list for test availability below.

Take the LBD Blood Test

If my mind can conceive it, and my heart can believe it, then I can achieve it.
Mohammad Ali - Fighter of Parkinson's
Muhammad Ali

Sign up for SYNTap-Blood Test

Get email alerts on testing availability.